Premium
Imatinib mesylate in children and adolescents with cancer
Author(s) -
Barr Ronald D.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22484
Subject(s) - medicine , imatinib , imatinib mesylate , myeloid leukemia , tyrosine kinase inhibitor , oncology , philadelphia chromosome , tyrosine kinase , leukemia , cancer , platelet derived growth factor receptor , cancer research , receptor , chromosomal translocation , growth factor , gene , genetics , biology
Imatinib is an inhibitor of the BCR–ABL fusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c‐KIT and platelet‐derived growth factor (PDGF) receptor. The drug is now included as front‐line therapy for CML and Philadelphia chromosome‐positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues for further study. European and North American consortia have conducted phase I and II clinical trials of imatinib in children and adolescents with brain and other solid tumors that have provided little evidence of efficacy. Pediatr Blood Cancer 2010;55:18–25. © 2010 Wiley‐Liss, Inc.